Plasma B-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects comparison with Albuminuria

International Heart Journal

Volumn 53, Issue 3, 2012, Pages 176-181

  Onodera, Masayuki ^a   Nakamura, Motoyuki ^a   Tanaka, Fumitaka ^a   Takahashi, Tomohiro ^a   Makita, Shinji ^a   Ishisone, Takenori ^a   Ishibashi, Yasuhiro ^a   Itai, Kazuyoshi ^a   Onoda, Toshiyuki ^a   Ohsawa, Masaki ^a   Tanno, Kozo ^a   Sakata, Kiyomi ^a   Omama, Shinichi ^b   Ogasawara, Kuniaki ^b   Ogawa, Akira ^b   Kuribayashi, Toru ^a   Sakamaki, Kentaro ^c   Okayama, Akira ^c  

^a IWATE UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Longitudinal study; Myocardial infarction; Stroke

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN A1C;

ACUTE HEART INFARCTION; ADULT; AGED; ALBUMINURIA; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMMUNITY LIVING; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STROKE; URINE ALBUMIN TO CREATININE RATIO;

AGED; ALBUMINURIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; ROC CURVE; STATISTICS AS TOPIC; STROKE;

EID: 84863437099     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.53.176     Document Type: Article

References (28)

1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
3. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
4. Sakuma M, Nakamura M, Tanaka F, et al. Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population. Circ J 2010; 74: 792-7.
5. Huelsmann M, Neuhold S, Strunk G, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 2008; 29: 2259-64.
6. Bhalla MA, Chiang A, Epshteyn VA, et al. Prognostic role of Btype natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004; 44: 1047-52.
7. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005; 48: 156-63.
8. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006; 49: 2256-62.
9. Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005; 48: 149-55.
10. Takahashi T, Nakamura M, Onoda T, et al. Predictive value of plasma B-type natriuretic peptide for ischemic stroke: a communitybased longitudinal study. Atherosclerosis 2009; 207: 298-303.
11. Ohsawa M, Itai K, Tanno K, et al. Cardiovascular risk factors in the Japanese northeastern rural population. Int J Cardiol 2009; 137: 226-35.
12. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-67.
13. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-92.
14. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-53.
15. Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10: 414-8.
16. Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care 1992; 15: 1581-4.
17. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.
18. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
19. Omama S, Yoshida Y, Ogawa A, Onoda T, Okayama A. Differences in circadian variation of cerebral infarction, intracerebral haemorrhage and subarachnoid haemorrhage by situation at onset. J Neurol Neurosurg Psychiatry 2006; 77: 1345-9.
20. Nakamura M, Hiramori K. Natriuretic peptide measurement as a screening test for overt and subclinical heart failure. Int J Cardiol 2003; 92: 9-15. (Review)
21. Rana BS, Davies JI, Band MM, Pringle SD, Morris A, Struthers AD. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 2006; 92: 916-20.
22. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002; 87: 131-5.
23. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two communitybased studies. J Clin Endocrinol Metab 2011; 96: 3242-9.
24. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-9.
25. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001 25; 286: 421-6.
26. Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 2007; 28: 1678-82.
27. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007; 167: 1545-51.
28. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48: 1703-11. (Review)